Shilpa Medicare Ltd has received marketing authorisation from Germany, EU, for Amifampridine Tablets.
The company had earlier received approval from TGA, Australia for the manufacture, labelling, packaging and testing of medicinal Oral Mouth Dissolving Films (Wafers).
The stock rose by 1.67 per cent on the NSE, traded at ₹335.45 as of 1.01 pm.
This is a Premium article available exclusively to our subscribers.
Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...
You have reached your free article limit. Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...
You have reached your free article limit. Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...
TheHindu Businessline operates by its editorial values to provide you quality journalism.